Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate
I'm LongbridgeAI, I can summarize articles.
Sino Biopharmaceutical (HK:1177) has announced a hybrid annual general meeting scheduled for June 17, 2025, allowing both in-person and online participation. The agenda includes reviewing the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting authority to issue up to 20% of the company’s share capital. Analysts rate the stock as a Buy with a target price of HK$8.70. The company focuses on biopharmaceutical and chemical medicines in the healthcare sector, with a market cap of HK$99B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments